Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18288663 | 0.94 | ALDH1A1 (0.65) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL18292191 | 0.94 | MAPT (0.59) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL5008292 | 0.82 | MEN1 (0.77) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL1411294 | 0.80 | MEN1 (0.72) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL18288648 | 0.79 | KMT2A (0.69) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL8661871 | 0.79 | MEN1 (0.82) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL8401925 | 0.77 | KMT2A (0.79) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL2351620 | 0.77 | MEN1 (0.79) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL20548265 | 0.76 | MEN1 (0.66) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL21590314 | 0.76 | MEN1 (0.83) | KMT2AMEN1MAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355464-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160355464-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355464-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | KMT2A 1588/4885MEN1 3008/4885MAPT 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.